Shifting Physician Prescribing to a Preferred Histamine-2-Receptor Antagonist

OBJECTIVES: This study was undertaken to determine whether a program of education, therapeutic reevaluation of eligible patients, and performance feedback could shift prescribing to cimetidine from other histamine-2 receptor antagonists, which commonly are used in the management of ulcers and reflux, and reduce costs without increasing rates of ulcer-related hospital admissions. METHODS: This study used an interrupted monthly time series with comparison series in a large mixed-model health maintenance organization. Physicians employed in health centers (staff model) and physicians in independent medical groups contracting to provide health maintenance organization services (group model) participated. The comparative percentage prescribed of specific histamine-2 receptor antagonists (market share), total histamine-2 receptor antagonist prescribing, cost per histamine-2 receptor antagonist prescription, and the rate of hospitalization for gastrointestinal illness were assessed. RESULTS: In the staff model, therapeutic reevaluation resulted in a sudden increase in market share of the preferred histamine-2 receptor antagonist cimetidine (+53.8%) and a sudden decrease in ranitidine (-44.7%) and famotidine (-4.8%); subsequently, cimetidine market share grew by 1.1% per month. In the group model, therapeutic reevaluation resulted in increased cimetidine market share (+9.7%) and decreased prescribing of other histamine-2 receptor antagonists (ranitidine -11.6%; famotidine -1.2%). Performance feedback did not result in further changes in prescribing in either setting. Use of omeprazole, an expensive alternative, essentially was unchanged by the interventions, as were overall histamine-2 receptor antagonist prescribing and hospital admissions for gastrointestinal illnesses. This intervention, which cost approximately $60,000 to implement, resulted in estimated annual savings in histamine-2 receptor antagonist expenditures of $1.06 million. CONCLUSIONS: Annual savings in histamine-2 receptor antagonist expenditures after this multifaceted intervention were more than implementation costs, with no discernible effects on numbers of hospitalizations. The magnitude of effect and cost savings were much greater in the staff model; organizational factors and economic incentives may have contributed to these differences. More research is needed to determine the generalizability of this approach to other technologies and managed care settings

Antagonist · Histamine · Receptor · Clinical Nutrition and Gastroenterology · Gastroesophageal reflux and treatments · Helicobacter pylori-related gastroenterology studies · Internal Medicine · Medicine · Pharmacology

• Segmented regression analysis of interrupted time series studies in medication use research

  Open Access•Anita K Wagner, Stephen B Soumerai et al.•Journal of Clinical Pharmacy and…•2002

  Incluir item

• Changes in self-reported drinking behaviors among US teenagers associated with the introduction of flavored malt beverages

  Jane Z Dumsha, Robert A DiTomasso et al.•Addiction Research & Theory•2010

  Incluir item

• Personal, Organizational, and Market Level Influences on Physicians’ Practice Patterns

  Bruce E Landon, James Reschovsky et al.•Medical Care•2001

  Incluir item

• Cluster Randomized Trials in Comparative Effectiveness Research

  Richard Platt, Samuel U Takvorian et al.•Medical Care•2010

  Incluir item

• The Effect of an Education and Feedback Intervention on Group-Model and Network-Model Health Maintenance Organization Physician Prescribing Behavior

  Joel M Schectman, Neeraj K Kanwal et al.•Medical Care•1995

  Incluir item